Legal Representation
Attorney
Brooks R. Bruneau
USPTO Deadlines
Next Deadline
1644 days remaining
Section 8 & 9 (20-Year) Renewal Due (Based on registration date 2010-05-11)
Due Date
May 11, 2030
Grace Period Ends
November 11, 2030
Application History
31 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 29, 2020 | NA89 | E | NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED | Loading... |
| Jun 29, 2020 | 89AG | O | REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED | Loading... |
| Jun 29, 2020 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | Loading... |
| Jun 29, 2020 | RNL1 | Q | REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) | Loading... |
| Apr 17, 2020 | E89R | I | TEAS SECTION 8 & 9 RECEIVED | Loading... |
| May 11, 2019 | REM2 | E | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | Loading... |
| Jul 6, 2016 | C15P | O | REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | Loading... |
| Jul 6, 2016 | NA85 | E | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | Loading... |
| Jul 5, 2016 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | Loading... |
| May 10, 2016 | E815 | I | TEAS SECTION 8 & 15 RECEIVED | Loading... |
| May 11, 2010 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Feb 23, 2010 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Feb 23, 2010 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jan 15, 2010 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Jan 14, 2010 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Dec 23, 2009 | ACEC | I | AMENDMENT FROM APPLICANT ENTERED | Loading... |
| Dec 23, 2009 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Dec 17, 2009 | I | PAPER RECEIVED | Loading... | |
| Jun 15, 2009 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jun 15, 2009 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Jun 15, 2009 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| May 23, 2009 | ACEC | I | AMENDMENT FROM APPLICANT ENTERED | Loading... |
| May 23, 2009 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| May 18, 2009 | ALIE | A | ASSIGNED TO LIE | Loading... |
| May 15, 2009 | I | PAPER RECEIVED | Loading... | |
| Nov 13, 2008 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Nov 13, 2008 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Nov 13, 2008 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Nov 5, 2008 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Aug 1, 2008 | MDSC | O | NOTICE OF DESIGN SEARCH CODE MAILED | Loading... |
| Jul 31, 2008 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
[ Enzymatic preparations for scientific and research purposes in the medical, or pharmaceutical fields ]
Class 005
[ Pharmaceutical products for the treatment of cardiovascular diseases, dermatological diseases, disorders in the central nervous system, cancers, asthma, allergies, lipidic disorders, obesity and diabetes; sanitary preparations for medical use; biological preparations for medical use; slimming medical preparations, namely, diet pills, tablets, sachets of powder, capsules, syrups; cultures of microorganisms for medical, pharmaceutical or veterinary use; culture media for use in bacteriology; cell culture preparations of eucaryotic cell lines or microorganisms for medical or pharmaceutical use, in particular in gene therapy and cell therapy; biologically active compounds being components of pharmaceutical preparations for treating metabolic disorders in human beings and animals, in particular in the case of cardiovascular diseases, dermatological diseases, disorders in the central nervous system, cancers, asthma, allergies, lipidic disorders, obesity and diabetes; kits comprising cells, nucleic acids, proteins or reagents for the preparation or the selection of biologically active compounds or cells for medical purposes; diagnostic preparations for medical use comprising chemical reagents for in-vivo, ex-vivo or in-vitro use; diagnosis reagents for medical or veterinary use; sanitary preparations for medical use; dietetic substances for medical use; dietetic foodstuffs for medical use; food supplements for medical use; enzyme preparations for medical or veterinary use, namely, enzyme food supplements and animal feed additives in the nature of enzymes for use in animal feeds to assist in digestion ]
Class 042
Pharmaceutical research for the discovery of new drugs; scientific research, in particular in the medical, biomedical, chemical, genetic, pharmaceutical [ or veterinary ] fields; basic and applied research in the medical field; [ technical research in the scientific field; ] pharmaceutical research for the screening and selection of molecules for drug development; scientific research for the development and validation of biological tests, of cell tests and of genetic tests; [ development of new technology for others in the field of functional genomics to identity, characterize, validate or develop biologically active molecules; ] biological research via analysis of biological substances in biologic fluids [ ; computer programming in the field of scientific research and for the pharmaceutical industry; analysis of technical medical products or processes for scientific and research purposes in the medical, pharmaceutical or biotechnological fields; professional consultancy, not connected with the conduct of business, in the fields of scientific research and for the pharmaceutical industry; research and development of new pharmaceutical products for third parties; rental of computer hardware, namely, access time to a scientific data base server centre ]
Additional Information
Design Mark
The mark consists of the word "GENFIT" and a portion of the partial sphere appearing in blue. The words "Towards Better Medicine" and a portion of the partial sphere appearing in orange. The slanted lining on the partial sphere appears in white.
Color Claim
The color(s) Blue, white and orange is/are claimed as a feature of the mark.
Classification
International Classes
001
005
042